AU2001270413A1 - Improved liposomal camptothecins and uses thereof - Google Patents
Improved liposomal camptothecins and uses thereofInfo
- Publication number
- AU2001270413A1 AU2001270413A1 AU2001270413A AU7041301A AU2001270413A1 AU 2001270413 A1 AU2001270413 A1 AU 2001270413A1 AU 2001270413 A AU2001270413 A AU 2001270413A AU 7041301 A AU7041301 A AU 7041301A AU 2001270413 A1 AU2001270413 A1 AU 2001270413A1
- Authority
- AU
- Australia
- Prior art keywords
- improved liposomal
- liposomal camptothecins
- camptothecins
- improved
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21555600P | 2000-06-30 | 2000-06-30 | |
US60/215,556 | 2000-06-30 | ||
US26461601P | 2001-01-26 | 2001-01-26 | |
US60/264,616 | 2001-01-26 | ||
PCT/CA2001/000981 WO2002002078A2 (en) | 2000-06-30 | 2001-06-29 | Improved liposomal camptothecins and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001270413A1 true AU2001270413A1 (en) | 2002-01-14 |
Family
ID=26910152
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001270385A Expired AU2001270385B2 (en) | 2000-06-30 | 2001-06-29 | Liposomal antineoplastic drugs and uses thereof |
AU2001270413A Abandoned AU2001270413A1 (en) | 2000-06-30 | 2001-06-29 | Improved liposomal camptothecins and uses thereof |
AU7038501A Pending AU7038501A (en) | 2000-06-30 | 2001-06-29 | Liposomal antineoplastic drugs and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001270385A Expired AU2001270385B2 (en) | 2000-06-30 | 2001-06-29 | Liposomal antineoplastic drugs and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU7038501A Pending AU7038501A (en) | 2000-06-30 | 2001-06-29 | Liposomal antineoplastic drugs and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (7) | US7244448B2 (en) |
EP (2) | EP1299085B1 (en) |
JP (3) | JP2004501955A (en) |
CN (1) | CN1245977C (en) |
AT (2) | ATE309786T1 (en) |
AU (3) | AU2001270385B2 (en) |
CA (2) | CA2412790C (en) |
DE (2) | DE60115044T2 (en) |
ES (1) | ES2253398T3 (en) |
IL (2) | IL153676A0 (en) |
MX (1) | MXPA02012817A (en) |
WO (2) | WO2002002078A2 (en) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US6723338B1 (en) * | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
ATE309786T1 (en) * | 2000-06-30 | 2005-12-15 | Inex Pharmaceuticals Corp | LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF |
US7452550B2 (en) * | 2000-06-30 | 2008-11-18 | Hana Biosciences, Inc. | Liposomal antineoplastic drugs and uses thereof |
US20030059375A1 (en) * | 2001-08-20 | 2003-03-27 | Transave, Inc. | Method for treating lung cancers |
US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
BRPI0313191A2 (en) * | 2002-08-02 | 2016-11-08 | Transave Inc | composition and process for producing a platinum aggregate and pharmaceutical formulation |
US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
US7179484B2 (en) * | 2002-11-06 | 2007-02-20 | Azaya Therapeutics, Inc. | Protein-stabilized liposomal formulations of pharmaceutical agents |
WO2005002546A1 (en) * | 2003-06-27 | 2005-01-13 | Smithkline Beecham Corporation | Stabilized topotecan liposomal composition and methods |
ATE434431T1 (en) * | 2003-11-14 | 2009-07-15 | Het Nl Kanker I The Netherland | PHARMACEUTICAL FORMULATIONS CONTAINING SHORT CHAIN SPHINGOLIPIDS AND USE THEREOF |
WO2005072776A2 (en) * | 2004-01-30 | 2005-08-11 | Instytut Farmaceutyczny | Liposomal formulations of the antineoplastic agents |
US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
CN1976711A (en) * | 2004-03-18 | 2007-06-06 | 特兰萨维股份有限公司 | Administration of cisplatin by inhalation |
US20070065522A1 (en) * | 2004-03-18 | 2007-03-22 | Transave, Inc. | Administration of high potency platinum compound formulations by inhalation |
CN103948545B (en) | 2004-05-03 | 2017-10-03 | 益普生生物制药公司 | Liposome for drug delivery |
EP1750673B1 (en) * | 2004-05-17 | 2009-12-02 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
CN101001633A (en) * | 2004-05-21 | 2007-07-18 | 特兰萨夫公司 | Treatment of lung diseases and pre-lung disease conditions |
CN1960729B (en) * | 2004-06-01 | 2012-04-11 | 泰尔茂株式会社 | Irinotecan preparation |
EP1773298A1 (en) * | 2004-08-06 | 2007-04-18 | Biospectrum, Inc. | Multiple layered liposome and preparation method thereof |
US8349360B2 (en) * | 2004-10-06 | 2013-01-08 | Bc Cancer Agency | Liposomes with improved drug retention for treatment of cancer |
JP4990786B2 (en) * | 2004-11-05 | 2012-08-01 | イネックス ファーマシューティカルズ コーポレイション | Compositions and methods for stabilizing drug liposome formulations |
MX2007004955A (en) * | 2004-11-08 | 2007-06-14 | Transave Inc | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally. |
CN100348194C (en) * | 2005-07-26 | 2007-11-14 | 康辰医药发展有限公司 | Lipid formulation of nolatrexed dihydrochloride and its preparation method |
CN100375621C (en) * | 2005-11-04 | 2008-03-19 | 唐星 | Vinorelbine liposome micro ball injection and its prepn |
WO2007056264A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
US9107824B2 (en) * | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
FR2895258B1 (en) | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS |
JP2009535360A (en) * | 2006-04-26 | 2009-10-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutic agents |
WO2008070009A2 (en) * | 2006-12-01 | 2008-06-12 | Alza Corporation | Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes |
US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
US20100093873A1 (en) * | 2008-10-02 | 2010-04-15 | Goldfischer Sidney L | Methods of improving therapy of perfluorocarbons (PFC) |
US20110223675A1 (en) * | 2008-11-20 | 2011-09-15 | Terumo Kabushiki Kaisha | Drug release means from liposomes and method for evaluating releasability |
EP2524280A1 (en) | 2010-01-14 | 2012-11-21 | BrainLAB AG | Controlling a surgical navigation system |
EP2632264B1 (en) | 2010-10-29 | 2019-10-02 | Health Research, Inc. | Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy |
PL226015B1 (en) | 2011-03-03 | 2017-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | Liposome preparation containing anticancer active substance, process for the preparation thereof and pharmaceutical compositions containing thereof |
US8753674B2 (en) * | 2011-06-03 | 2014-06-17 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current |
US10238602B2 (en) * | 2011-06-03 | 2019-03-26 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies |
US10349884B2 (en) * | 2011-06-03 | 2019-07-16 | Sighpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
US10117881B2 (en) | 2011-06-03 | 2018-11-06 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies |
US10449193B2 (en) * | 2011-06-03 | 2019-10-22 | Signpath Pharma Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
US11291644B2 (en) | 2012-09-04 | 2022-04-05 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
MX2015005992A (en) | 2012-11-20 | 2016-03-07 | Spectrum Pharmaceuticals Inc | Improved method for the preparation of liposome encapsulated vincristine for therapeutic use. |
US10413509B2 (en) * | 2013-05-30 | 2019-09-17 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
CA2933204C (en) | 2013-12-18 | 2020-04-28 | Signpath Pharma, Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
CA2950758C (en) | 2014-06-03 | 2020-04-28 | Signpath Pharma, Inc. | Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies |
FI3229776T3 (en) * | 2014-11-25 | 2023-08-15 | Curadigm Sas | Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof |
US11318131B2 (en) * | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
TWI678213B (en) | 2015-07-22 | 2019-12-01 | 美商史倍壯製藥公司 | A ready-to-use formulation for vincristine sulfate liposome injection |
WO2017031445A1 (en) | 2015-08-20 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Combination therapy for cancer treatment |
CN108495629A (en) | 2015-08-21 | 2018-09-04 | 益普生生物制药有限公司 | Use the method comprising liposome Irinotecan and the combination therapy to treat metastatic cancer of pancreas of oxaliplatin |
CA2940470C (en) * | 2015-09-18 | 2019-08-20 | Signpath Pharma Inc. | Treatment for glioblastoma |
EP3362049A1 (en) | 2015-10-16 | 2018-08-22 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
US11806401B2 (en) | 2016-04-27 | 2023-11-07 | Signpath Pharma, Inc. | Prevention of drug-induced atrio-ventricular block |
PT3506909T (en) | 2016-09-02 | 2022-08-16 | Dicerna Pharmaceuticals Inc | 4'-phosphate analogs and oligonucleotides comprising the same |
JP2019533684A (en) | 2016-11-02 | 2019-11-21 | イプセン バイオファーム リミティド | Treatment of gastric cancer with combination therapy including liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) |
CN116763733A (en) | 2017-03-31 | 2023-09-19 | 富士胶片株式会社 | Liposome composition and pharmaceutical composition |
EP3752158A4 (en) * | 2018-02-14 | 2022-03-09 | L.E.A.F Holdings Group LLC | Gamma polyglutamated aminopterin and uses thereof |
TWI737974B (en) * | 2018-04-09 | 2021-09-01 | 美商標徑製藥公司 | Dosing regimens for treatment of proliferative disorders |
WO2019200043A1 (en) * | 2018-04-11 | 2019-10-17 | New Mexico Tech University Research Park Coporation | Lipid prodrugs for use in drug delivery |
EP3811931A4 (en) | 2018-06-20 | 2021-08-04 | FUJIFILM Corporation | Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor |
JP7057434B2 (en) | 2018-10-01 | 2022-04-19 | 富士フイルム株式会社 | Combination drug containing a liposome composition containing a drug and a platinum preparation |
JP2022527108A (en) | 2019-03-29 | 2022-05-30 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Compositions and Methods for the Treatment of KRAS-Related Diseases or Disorders |
KR20220004675A (en) | 2019-05-03 | 2022-01-11 | 다이서나 파마수이티컬, 인크. | Double-Stranded Nucleic Acid Inhibitor Molecules with a Single Sense Strand |
CN115461042A (en) * | 2019-12-20 | 2022-12-09 | 翻译生物公司 | Improved method for preparing MRNA-loaded lipid nanoparticles |
EP4090665A1 (en) | 2020-01-15 | 2022-11-23 | Dicerna Pharmaceuticals, Inc. | 4'-o-methylene phosphonate nucleic acids and analogues thereof |
IL300283A (en) | 2020-08-04 | 2023-04-01 | Dicerna Pharmaceuticals Inc | Systemic delivery of oligonucleotides |
JPWO2022250013A1 (en) | 2021-05-24 | 2022-12-01 | ||
WO2022250015A1 (en) | 2021-05-24 | 2022-12-01 | 富士フイルム株式会社 | Treatment agent |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5023087A (en) * | 1986-02-10 | 1991-06-11 | Liposome Technology, Inc. | Efficient method for preparation of prolonged release liposome-based drug delivery system |
AU7128887A (en) * | 1986-02-10 | 1987-08-25 | Liposome Technology, Inc. | Controlled-release liposome delivery system |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5552154A (en) * | 1989-11-06 | 1996-09-03 | The Stehlin Foundation For Cancer Research | Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof |
US5552156A (en) | 1992-10-23 | 1996-09-03 | Ohio State University | Liposomal and micellular stabilization of camptothecin drugs |
WO1995008986A1 (en) | 1993-09-27 | 1995-04-06 | Smithkline Beecham Corporation | Camptothecin formulations |
US6855331B2 (en) * | 1994-05-16 | 2005-02-15 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
CZ104197A3 (en) * | 1994-10-05 | 1997-09-17 | Glaxo Wellcome Inc | Pharmaceutical preparation |
US5972379A (en) * | 1995-02-14 | 1999-10-26 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering a quinolone |
ATE285477T1 (en) * | 1995-06-07 | 2005-01-15 | Inex Pharmaceutical Corp | PRODUCTION OF LIPID-NUCLIC ACID PARTICLES USING A HYDROPHOBIC LIPID-NUCLIC ACID COMPLEX INTERMEDIATE PRODUCT AND FOR USE IN GENE TRANSFER |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
CA2269758C (en) * | 1996-10-22 | 2008-01-08 | Hermes Biosciences, Inc. | Liposome compositions comprising ionizable compounds in stable precipitated form and methods for their preparation |
US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
CA2303366A1 (en) * | 1997-09-16 | 1999-03-25 | Nexstar Pharmaceuticals, Inc. | Liposomal camptothecin formulations |
WO2000023052A1 (en) * | 1998-09-16 | 2000-04-27 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
US6723338B1 (en) * | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
US6352996B1 (en) * | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
US6191119B1 (en) * | 1999-10-15 | 2001-02-20 | Supergen, Inc. | Combination therapy including 9-nitro-20(S)-camptothecin |
ATE309786T1 (en) * | 2000-06-30 | 2005-12-15 | Inex Pharmaceuticals Corp | LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF |
BR0114713A (en) * | 2000-10-16 | 2004-01-13 | Neopharm Inc | Liposomal formulation of mitoxantrone |
US6825206B1 (en) * | 2000-11-16 | 2004-11-30 | Research Triangle Institute | Camptothecin compounds with a thioether group |
US6627614B1 (en) * | 2002-06-05 | 2003-09-30 | Super Gen, Inc. | Sequential therapy comprising a 20(S)-camptothecin and an anthracycline |
-
2001
- 2001-06-29 AT AT01949141T patent/ATE309786T1/en not_active IP Right Cessation
- 2001-06-29 WO PCT/CA2001/000981 patent/WO2002002078A2/en active IP Right Grant
- 2001-06-29 US US09/896,812 patent/US7244448B2/en not_active Expired - Lifetime
- 2001-06-29 EP EP01949169A patent/EP1299085B1/en not_active Expired - Lifetime
- 2001-06-29 MX MXPA02012817A patent/MXPA02012817A/en active IP Right Grant
- 2001-06-29 AT AT01949169T patent/ATE309787T1/en not_active IP Right Cessation
- 2001-06-29 IL IL15367601A patent/IL153676A0/en active IP Right Grant
- 2001-06-29 CN CNB018138187A patent/CN1245977C/en not_active Expired - Lifetime
- 2001-06-29 AU AU2001270385A patent/AU2001270385B2/en not_active Expired
- 2001-06-29 ES ES01949169T patent/ES2253398T3/en not_active Expired - Lifetime
- 2001-06-29 AU AU2001270413A patent/AU2001270413A1/en not_active Abandoned
- 2001-06-29 US US09/896,811 patent/US7060828B2/en not_active Expired - Lifetime
- 2001-06-29 CA CA2412790A patent/CA2412790C/en not_active Expired - Lifetime
- 2001-06-29 CA CA2412795A patent/CA2412795C/en not_active Expired - Lifetime
- 2001-06-29 DE DE60115044T patent/DE60115044T2/en not_active Expired - Lifetime
- 2001-06-29 JP JP2002506699A patent/JP2004501955A/en not_active Withdrawn
- 2001-06-29 EP EP01949141A patent/EP1299084B1/en not_active Expired - Lifetime
- 2001-06-29 AU AU7038501A patent/AU7038501A/en active Pending
- 2001-06-29 DE DE60115045T patent/DE60115045T2/en not_active Expired - Lifetime
- 2001-06-29 WO PCT/CA2001/000925 patent/WO2002002077A2/en active IP Right Grant
-
2002
- 2002-12-26 IL IL153676A patent/IL153676A/en unknown
-
2004
- 2004-02-27 US US10/788,649 patent/US20040170678A1/en not_active Abandoned
-
2005
- 2005-12-06 US US11/294,826 patent/US20060093662A1/en not_active Abandoned
-
2006
- 2006-05-08 US US11/429,911 patent/US20060269594A1/en not_active Abandoned
-
2010
- 2010-12-09 US US12/963,888 patent/US20110086826A1/en not_active Abandoned
-
2012
- 2012-02-09 JP JP2012025785A patent/JP2012092148A/en active Pending
- 2012-06-28 US US13/536,325 patent/US20130136787A1/en not_active Abandoned
-
2014
- 2014-02-17 JP JP2014027576A patent/JP2014088444A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001270413A1 (en) | Improved liposomal camptothecins and uses thereof | |
AU2002213336A1 (en) | Substituted heterocyclic compounds for treating multidrug resistance | |
AU2001256975A1 (en) | Compositions and methods for inhibition of cancer invasion and angiogenesis | |
WO2000076933A3 (en) | Water-resistant gypsum composition | |
AU3652102A (en) | Compounds and their uses | |
WO2002008190A3 (en) | Novel heteroaryl derivatives and use thereof as anti-tumour agents | |
WO2006052767A3 (en) | Compositions and methods for stabilizing liposomal camptothecin formulations | |
WO2001087882A3 (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
HK1069169A1 (en) | Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors | |
AU2002219418A1 (en) | Compositions of estrogen-cyclodextrin complexes | |
IL153680A0 (en) | Aplidine derivatives and methods for the preparation thereof | |
WO2002051983A3 (en) | Novel compounds and compositions as cathepsin inhibitors | |
ZA200404752B (en) | 6-aminomorphinane derivatives method for the production and use thereof | |
IL160171A0 (en) | Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
AU2001250821A1 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
BG105731A (en) | 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives | |
WO2004032908A3 (en) | Method of inhibiting angiogenesis | |
NZ530587A (en) | Diazacycloalkanes as oxytocin agonists | |
AU2002210425A1 (en) | Novel beta-amyloid inhibitors, method for producing the same and the use thereofas medicaments | |
WO2001097789A3 (en) | Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors | |
MXPA03005374A (en) | Antitumoral carbazoles. | |
AU2001294062A1 (en) | Method of treating aqueous compositions | |
WO2001068066A3 (en) | A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer | |
CA2548078A1 (en) | Pharmaceutical formulations of camptothecins and process for making same | |
IL154165A0 (en) | Method for the production of imidazo-(1,2-c) (2,3)-benzodiazepines and intermediates in the production thereof |